Shanmugam Muthusamy

COO-Novitium Ops Shanmugam Muthusamy sold 100,000 shares (18.8% of holdings) for $9.0M at $90.36 avg on Aug 20-21

Shanmugam Muthusamy, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, executed 2 separate sales totaling 100,000 shares for $9,036,007.96 at a blended average price of $90.36, reducing his holdings by 18.8% to 431,920 shares post-transaction. The timing is noteworthy: the current price of $91.01 is -0.1% from the 52-week high of $91.14, and the stock has gained 36.0% over the prior 30 days and 57.5% over the prior 90 days. Across Muthusamy's same-ticker history at ANIP, his 3 prior measurable sales (July 2024) all delivered negative 90-day returns ranging from -5.0% to -9.8%, and his cross-ticker track record shows a 77.78% well-timed sell rate with an average 90-day return of -4.0%. The sale occurs near the stock's all-time recent highs, against a backdrop of strong recent momentum, suggesting the insider is liquidating a material portion of his stake during an elevated valuation window.

COO Shanmugam Muthusamy sold 100,000 shares (15.8% of holdings) for $8.8M at $88.25 avg, stock at 52-week high; mixed timing pattern at this ticker

Shanmugam Muthusamy, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, executed two separate sales totaling 100,000 shares for $8,824,533.30 on consecutive days (August 14–15, 2025), reducing his position by 15.8% from 631,920 to 531,920 shares. The sales occurred when the stock was trading at the upper edge of its 52-week range ($89.48–$87.15 transaction prices vs. $53.35–$90.00 range), within 0.3% of the 52-week high. At the same-ticker level, Muthusamy's prior 5 trades at ANIP show 3 of 5 were well-timed at the 90-day mark, but the two most recent (June 2024) posted positive 90-day returns (+2.5%, +2.0%), suggesting the stock rallied after those sales. The current trade's timing remains to be assessed, but the pattern of mixed outcomes at this specific ticker (neither consistently well- nor poorly timed) warrants observation against upcoming price action and company performance as ANIP reported full-year unprofitability despite latest-quarter revenue of $211.4M and 26.2% annual growth.

COO/Head of R&D sells 47,257 shares in 3 tranches for $3,011,592.12 over 3 days at ANIP

Shanmugam Muthusamy, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, executed 3 separate sales totaling 47,257 shares for $3,011,592.12 across July 15–17, 2024, at a blended average price of $63.73. The sales reduced his holdings from 682,620 to 635,363 shares, a -6.9% reduction. At the current price of $62.98, the stock trades -9.6% from its 52-week high of $69.69, suggesting the insider sold near recent highs. His cross-ticker track record shows 20 prior open-market sells with a 54.55% well-timed rate (stock declined after the sale), though 90-day measurement capability is limited by time elapsed. At ANIP specifically, his prior 5 recent trades (all sells in May–June 2024) show mixed near-term outcomes but no measurable 90-day pattern yet. With the stock at a P/E of 43.14 and annual revenue growth of +53.9%, the company's valuation remains elevated; the insider's measured reduction in holdings warrants observation to assess whether this reflects confidence in current levels or signals management's assessment of fair value.

Head of R&D/COO-Novitium Ops sold 20,000 shares of ANIP at $58.90 on 2024-06-21 (total $1.2M); retains 682.6K shares post-sale.

Shanmugam Muthusamy sold 20,000 shares (-2.8% of pre-transaction holdings) on 2024-06-21 at $58.90, reducing his ANIP position from 702.6K to 682.6K shares while retaining substantial holdings. This sale occurred 3 days into a cluster of five ANIP sales within a 35-day window (2024-05-17 through 2024-06-21), suggesting a pattern of periodic liquidations rather than a single event. The company fundamentals show strong growth (annual revenue +53.9%, net income $18.2M on $137.4M quarterly revenue) and modest valuation (P/E 43.03), though the stock is currently -9.9% from its 52-week high of $69.69 and has declined -9.7% over 90 days. Across his broader open-market history, Muthusamy's 20 prior sells averaged +0.0% 30-day return and +8.4% 90-day return at a 25% well-timed rate, suggesting mixed predictive timing; his five same-ticker ANIP trades have not yet demonstrated a measurable pattern at the 90-day horizon.

Head of R&D/COO sold 30,000 shares (4.1% of holdings) across 3 sales totaling $1.8M at $60.59 avg; stock down 14.8% from 52-week high.

Shanmugam Muthusamy executed 3 separate sales totaling 30,000 shares for $1,817,662.60 at a blended average of $60.59 per share on 2024-06-17, 2024-06-18, and 2024-06-20, reducing his stake from 732.6K to 702.6K shares (-4.1%). The stock currently trades at $59.39, down 14.8% from its 52-week high of $69.69 and down 3.8% over the past 30 days. At this insider's cross-ticker level, his 20 prior sells have returned +0.9% on average over 30 days and +12.2% over 90 days, with a well-timed rate of 18.18%. However, at ANIP specifically, his 5 prior sells have shown negative or minimal near-term outcomes (30d range: -5.7% to +0.8%), with none yet measurable over 90 days. The company reports strong fundamentals—revenue growth of 53.9% annually, a P/E of 40.68, and recent quarterly revenue of $137.4M—but the execution timing of these three sequential sales in mid-June warrants monitoring against the subsequent price action and any material disclosures.